Clinical Trial Update: Clinical Trial of PCV24 in Infants Aged 2-23 Months [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial to evaluate the safety and immunogenicity of PCV24 in infants aged 2-23 months is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infection

Drugs mentioned

• PCV24 (24-valent pneumococcal conjugate vaccine)

Snippet

Sponsor: Sinovac Life Sciences Co., Ltd. | Conditions: Pneumococcal Infectious Disease | Phase 1 | Status: RECRUITING